HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer (Q36525801)

14 August 2017

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer (English)

1 reference

14 August 2017

1 reference

Young Kyung Bae

1

1 reference

14 August 2017

Gyungyub Gong

2

1 reference

14 August 2017

Jun Kang

3

1 reference

14 August 2017

Ahwon Lee

4

1 reference

14 August 2017

Eun Yoon Cho

5

1 reference

14 August 2017

Ji Shin Lee

6

1 reference

14 August 2017

Kwang-Sun Suh

7

1 reference

14 August 2017

Dong Wha Lee

8

1 reference

14 August 2017

Woo Hee Jung

9

1 reference

14 August 2017

Breast Pathology Study Group of Korean Society of Pathologists

10

1 reference

14 August 2017

31 December 2012

1 reference

14 August 2017

Journal of breast cancer

1 reference

14 August 2017

15

1 reference

14 August 2017

4

1 reference

14 August 2017

381-387

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

14 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3542844

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23346165

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Human epidermal growth factor receptor 2 testing: where are we?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23346165

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23346165

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4048/JBC.2012.15.4.381

1 reference

14 August 2017

1 reference

14 August 2017

PubMed publication ID

23346165

1 reference